#China #Shenzhen #MGI Tech #Swiss Rockets #CoolMPS

MGI Tech and Swiss Rockets AG: A New Era in Sequencing Technology

In a significant move set to redefine the landscape of genomic sequencing, MGI Tech Co., Ltd. has announced a strategic exclusive licensing agreement with Swiss Rockets AG, a biotech firm based in Switzerland. This partnership is poised to enhance the global reach of MGI's proprietary CoolMPSä sequencing technology, leveraging both companies' strengths in the life sciences sector.

The Essence of the Licensing Agreement

The agreement, executed via MGI's U.S. subsidiaries, MGI US LLC and Complete Genomics Inc., allows Swiss Rockets exclusive rights to develop, manufacture, and commercialize products utilizing the CoolMPS technology. Notably, this excludes markets in Asia-Pacific and Greater China, including Mainland China, Hong Kong, Macau, and Taiwan. This strategic alliance aims to unlock the full potential of CoolMPS technology, complementing MGI's acclaimed StandardMPSä technology and reinforcing its leadership position in genomic sequencing.

A Breakthrough in Sequencing Technology

CoolMPS technology is distinguished by its innovative use of antibody-based recognition chemistry, fundamentally addressing a prevalent issue in traditional long-read sequencing methods—DNA “scarring.” It utilizes nucleotides comprising natural bases alongside extension blocks and incorporates labeled antibodies that are base-specific and block-dependent. This cutting-edge methodology integrates each nucleotide with labeled multi-fluorescent dye antibodies, allowing for significantly enhanced sequencing capabilities.

When deployed on MGI's DNBSEQä platforms, CoolMPS is capable of generating sequencing reads of up to 600 to 700 bases. This capability opens doors to comprehensive genome, transcriptome, and microbiome analyses, enabling high-fidelity sequencing that is crucial for applications such as early cancer detection and monitoring through whole genome sequencing-based assays. For researchers, this means longer and more precise reads at a fraction of the cost of traditional methods.

Strengthening Global Health Solutions

The licensing agreement empowers Swiss Rockets to leverage MGI's CoolMPS-related intellectual property—including patents, proprietary know-how, and software—to innovate tailored products for global markets outside of the Asia-Pacific and Greater China regions. With support from a strategic investment agreement with Emergent BioSolutions, a leading U.S. public health company, Swiss Rockets aims to manufacture devices and consumables related to the CoolMPS technology. This gear will serve markets in the U.S. and Europe, further broadening the technology's applicability.

The advancements gained from CoolMPS will also play a pivotal role in enhancing personalized disease management and treatment, particularly in cancer and aging, marking a step toward precision medicine and longevity solutions.

Leadership Perspectives

Dr. Rade Drmanac, Chief Scientific Officer of MGI, highlighted the monumental significance of this partnership, emphasizing its role in maximizing the global impact of CoolMPS technology. He stated, "This collaboration is a major stride for MGI in enhancing the commercial viability of our groundbreaking sequencing technology, ultimately contributing to global health improvements. The renewed commitment to MGI from partners and stakeholders reaffirms our technological prominence and financial robustness."

In a similar vein, Dr. Vladimir Cmiljanovic, CEO of Swiss Rockets, expressed excitement about the potential of the CoolMPS licensing agreement. He affirmed, "Licensing CoolMPS from MGI enables us to enhance our oncology and viral disease innovation efforts through top-tier technology, further aligning with our drug development initiatives and diagnostic platforms aimed at delivering precise solutions for patients in need."

MGI and Swiss Rockets: Looking Ahead

As MGI Tech continues to spearhead innovations in life sciences, Swiss Rockets AG stands as a committed partner in expanding the reach and application of genomic technologies. Since its inception in 2016, MGI has established itself as a leader in the life sciences space, providing vital tools and technologies that serve a multitude of domains, including precision medicine, agriculture, and healthcare.

With CoolMPS technology at the forefront, both MGI Tech and Swiss Rockets AG are on a trajectory toward fostering significant advancements in the understanding and treatment of diseases, offering hope for better health outcomes on a global scale. This strategic partnership is not only a win for both companies but also a leap forward for the entire life sciences community.

For further updates on this groundbreaking initiative, MGI encourages stakeholders to stay informed via its official website and social media channels.